Globin Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 3.00 M
- Company Age 24 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 Cr
- Revenue Growth -5.90%
- Profit Growth -5.30%
- Ebitda 2.34%
- Net Worth 20.51%
- Total Assets 20.34%
About Globin Pharmaceuticals
Globin Pharmaceuticals Private Limited (GPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 23 March 2000 and has a history of 24 years and ten months. Its registered office is in Faridabad, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 3.00 M.
The company currently has active open charges totaling ₹1.00 Cr.
Sanjay Wadhwa and Vipin Wadhwa serve as directors at the Company.
Company Details
-
Location
Faridabad, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239HR2000PTC034453
-
Company No.
034453
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Mar 2000
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Globin Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Wadhwa
|
Director | 22-Dec-2005 | Current |
|
Vipin Wadhwa
|
Director | 22-Dec-2005 | Current |
Financial Performance of Globin Pharmaceuticals.
Globin Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 5.9% decrease. The company also saw a slight decrease in profitability, with a 5.3% decrease in profit. The company's net worth Soared by an impressive increase of 20.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Globin Pharmaceuticals?
In 2023, Globin Pharmaceuticals had a promoter holding of 36.27% and a public holding of 63.73%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹10.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 1.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Jul 2007 | Others | ₹1.00 Cr | Open |
How Many Employees Work at Globin Pharmaceuticals?
Globin Pharmaceuticals has a workforce of 8 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Globin Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Globin Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
